PubRank

Paola Piccini

Author PubWeight™ 61.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006 2.56
2 Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005 2.38
3 Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007 1.93
4 Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010 1.78
5 Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol 2008 1.77
6 Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002 1.74
7 Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011 1.66
8 Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012 1.63
9 Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014 1.58
10 Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res 2002 1.55
11 Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002 1.51
12 In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol 2010 1.47
13 Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008 1.45
14 Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010 1.41
15 Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010 1.40
16 Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011 1.32
17 Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002 1.30
18 Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011 1.22
19 Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008 1.15
20 Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord 2011 1.14
21 Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage 2012 1.13
22 Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003 1.13
23 Imaging microglial activation in Huntington's disease. Brain Res Bull 2006 1.12
24 Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry 2006 1.08
25 Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 2013 1.05
26 Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med 2012 1.02
27 Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003 0.98
28 The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain 2012 0.97
29 The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 2013 0.96
30 Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol 2012 0.96
31 PET image denoising using a synergistic multiresolution analysis of structural (MRI/CT) and functional datasets. J Nucl Med 2008 0.95
32 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002 0.92
33 Time trends of process and impact indicators in Italian mammography screening programmes--1996-2004. Epidemiol Prev 2007 0.91
34 Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol 2005 0.91
35 Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord 2005 0.91
36 Clinical peculiarities of tuberculosis. BMC Infect Dis 2014 0.89
37 Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009 0.88
38 Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013 0.87
39 Mammography screening in Italy: 2003-2004 survey. Epidemiol Prev 2006 0.86
40 Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2009 0.84
41 Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov Disord 2004 0.82
42 Towards molecular imaging of multiple sclerosis. Mult Scler 2011 0.82
43 Time trends of process and impact indicators in Italian breast screening programmes--1996-2005. Epidemiol Prev 2008 0.81
44 Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol Dis 2011 0.81
45 Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 2009 0.80
46 Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. J Neurol Neurosurg Psychiatry 2010 0.80
47 Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study. Neuropsychopharmacology 2010 0.79
48 Probabilistic classification learning with corrective feedback is associated with in vivo striatal dopamine release in the ventral striatum, while learning without feedback is not. Hum Brain Mapp 2014 0.79
49 In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res 2012 0.77
50 Positron emission tomography imaging in neurological disorders. J Neurol 2012 0.77
51 Ecstasy (MDMA) does not have long-term effects on aggressive interpretative bias: a study comparing current and ex-ecstasy users with polydrug and drug-naive controls. Exp Clin Psychopharmacol 2007 0.77
52 Single versus multiple impulse control disorders in Parkinson's disease: an ¹¹C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol 2015 0.77
53 Time trends of some indicators of mammography screening programmes in Italy, 1996-2003. Epidemiol Prev 2006 0.76
54 Brain imaging after neural transplantation. Prog Brain Res 2010 0.75
55 PET Imaging in Huntington's Disease. J Huntingtons Dis 2015 0.75
56 Time trends of process and impact indicators in Italian breast screening programmes: 1998-2007. Epidemiol Prev 2009 0.75
57 Audit system on Quality of breast cancer diagnosis and Treatment (QT): results of quality indicators on screen-detected lesions in Italy, 2007. Epidemiol Prev 2011 0.75
58 Old and new dopamine agonists in Parkinson's disease: a reappraisal. Introduction. Parkinsonism Relat Disord 2009 0.75